Literature DB >> 32342843

Prevalence, Etiology, and Outcome of Sepsis among Critically Ill Patients in Malawi.

Meghan Prin1, Lauren Onofrey2, Laura Purcell3, Clement Kadyaudzu4, Anthony Charles3.   

Abstract

There are scarce data describing the etiology and clinical sequelae of sepsis in low- and middle-income countries (LMICs). This study describes the prevalence and etiology of sepsis among critically ill patients at a referral hospital in Malawi. We conducted an observational prospective cohort study of adults admitted to the intensive care unit or high-dependency unit (HDU) from January 29, 2018 to March 15, 2018. We stratified the cohort based on the prevalence of sepsis as defined in the following three ways: quick sequential organ failure assessment (qSOFA) score ≥ 2, clinical suspicion of systemic infection, and qSOFA score ≥ 2 plus suspected systemic infection. We measured clinical characteristics and blood and urine cultures for all patients; antimicrobial sensitivities were assessed for positive cultures. During the study period, 103 patients were admitted and 76 patients were analyzed. The cohort comprised 39% male, and the median age was 30 (interquartile range: 23-40) years. Eighteen (24%), 50 (66%), and 12 patients (16%) had sepsis based on the three definitions, respectively. Four blood cultures (5%) were positive, two from patients with sepsis by all three definitions and two from patients with clinically suspected infection only. All blood bacterial isolates were multidrug resistant. Of five patients with urinary tract infection, three had sepsis secondary to multidrug-resistant bacteria. Hospital mortality for patients with sepsis based on the three definitions ranged from 42% to 75% versus 12% to 26% for non-septic patients. In summary, mortality associated with sepsis at this Malawi hospital is high. Bacteremia was infrequently detected, but isolated pathogens were multidrug resistant.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32342843      PMCID: PMC7356482          DOI: 10.4269/ajtmh.19-0605

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  36 in total

1.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Authors:  E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  India agrees to help Nigeria tackle the import of fake drugs.

Authors:  Abiodun Raufu
Journal:  BMJ       Date:  2003-06-07

3.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

4.  Mortality after fluid bolus in African children with severe infection.

Authors:  Kathryn Maitland; Sarah Kiguli; Robert O Opoka; Charles Engoru; Peter Olupot-Olupot; Samuel O Akech; Richard Nyeko; George Mtove; Hugh Reyburn; Trudie Lang; Bernadette Brent; Jennifer A Evans; James K Tibenderana; Jane Crawley; Elizabeth C Russell; Michael Levin; Abdel G Babiker; Diana M Gibb
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

Review 5.  Mycobacterium tuberculosis bacteremia in adults and children: a systematic review and meta-analysis.

Authors:  P B Pavlinac; E M Lokken; J L Walson; B A Richardson; J A Crump; G C John-Stewart
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

6.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.

Authors:  Carolin Fleischmann; André Scherag; Neill K J Adhikari; Christiane S Hartog; Thomas Tsaganos; Peter Schlattmann; Derek C Angus; Konrad Reinhart
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

7.  Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.

Authors:  Marya D Zilberberg; Andrew F Shorr; Scott T Micek; Cristina Vazquez-Guillamet; Marin H Kollef
Journal:  Crit Care       Date:  2014-11-21       Impact factor: 9.097

8.  Application of the qSOFA score to predict mortality in patients with suspected infection in a resource-limited setting in Malawi.

Authors:  Michaëla A M Huson; Chawezi Katete; Lilian Chunda; Jonathan Ngoma; Claudia Wallrauch; Tom Heller; Tom van der Poll; Martin P Grobusch
Journal:  Infection       Date:  2017-08-07       Impact factor: 3.553

9.  Antimicrobial resistance in Africa: a systematic review.

Authors:  Birkneh Tilahun Tadesse; Elizabeth A Ashley; Stefano Ongarello; Joshua Havumaki; Miranga Wijegoonewardena; Iveth J González; Sabine Dittrich
Journal:  BMC Infect Dis       Date:  2017-09-11       Impact factor: 3.667

10.  Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial.

Authors:  Ben Andrews; Matthew W Semler; Levy Muchemwa; Paul Kelly; Shabir Lakhi; Douglas C Heimburger; Chileshe Mabula; Mwango Bwalya; Gordon R Bernard
Journal:  JAMA       Date:  2017-10-03       Impact factor: 56.272

View more
  2 in total

1.  The Malawi emergency and critical care survey: A cross-sectional national facility assessment.

Authors:  Paul D Sonenthal; Mulinda Nyirenda; Noel Kasomekera; Regan H Marsh; Emily B Wroe; Kirstin W Scott; Alice Bukhman; Emilia Connolly; Tadala Minyaliwa; Martha Katete; Grace Banda-Katha; Joia S Mukherjee; Shada A Rouhani
Journal:  EClinicalMedicine       Date:  2022-01-13

2.  A retrospective study of ulinastatin for the treatment of severe sepsis.

Authors:  Chao Meng; Yi Qian; Wen-Hao Zhang; Ying Liu; Xiao-Chun Song; Han Liu; Xiang Wang
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.